Phd in NETWORK ONCOLOGY AND PRECISION MEDICINE

Education and training

1.    2009/10/01 – 2015/09/29: Degree in Medicine and Surgery, University of Rome “La Sapienza”, Faculty of Medicina e Psicologia, Rome, Italy.

2.    2015/11/01 – 2016/01/31: Medical Register in Rome, position number OMCEO ROMA M62285, University of Rome “La Sapienza”, Faculty of Medicina e Psicologia, Rome, Italy.

3.    2017/12/29 – 2023/01/19: Doctor in specialist training in Medical Oncology, University of Rome “La Sapienza”, Faculty of Farmacia e Medicina, Rome, Italy.

4.    2023/01/01 – 2025/12/31: PhD fellow in “Network Oncology and Precision Medicine”, University of Rome “La Sapienza”, Department of Experimental Medicine, Rome, Italy. Expected graduation: May 2026. Thesis: “Evaluation of Drug-Drug Interactions in Prostate Cancer patients during therapy with Abiraterone, Enzalutamide, Apalutamide or Darolutamide and Docetaxel using the Drug-PIN® software. An interim analysis of the DDI-AID study.”

Work experience

1.    2026/01/15 – Current: Research activity, Department of Medico-Surgical Sciences and Biotechnologies, Italy. Research activities, support for data analysis and statistical processing within the ARSI drug–drug interaction project in prostate cancer.

2.    2024/07/01 – Current: Oncologist, Villa del Rosario, Rome, Italy.

Skills
Language skills: Mother tongue Italian; other language English.
Research focus: Evaluation of the impact of drug-drug interactions in clinical practice and optimization of complex therapies by integrating genomic, molecular, and clinico‑pathological phenotype data.
Clinical expertise: Management of gastrointestinal and genitourinary cancers; care of the oncogeriatric population.
IT skills: Excellent command of Office package; excellent command of statistical analysis software; good command of R software.

Projects

1.    2023/11/08 – Current: “Evaluation of drug-drug interactions in prostate cancer patients during abiraterone, enzalutamide, apalutamide or darolutamide therapy using Drug-PIN software. The ‘DDI-AID’ study.” Role: Scientific Director and Study Coordinator (CET Lazio Area 1, Ref. 7364, 11/08/2023).

2.    2023/09/04 – Current: “Evaluation of clinical impact of drug-drug interactions in metastatic colorectal cancer patients during 5FU-based chemotherapy using Drug-PIN software: a pooled post-hoc analysis of TRIBE and TRIBE2 studies.” Role: Principal Investigator.

3.    2023/08/02 – Current: “Real-world data for never resectable mCRC patients during first line chemotherapy – A single Institution experience.” Role: Scientific Director and Sub-investigator (CET Lazio Area 1, Ref. 7299, 02/08/2023).

Clinical and research experience, mobility

1.    2023/09/03 – 2024/02/29: Research period at the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa. Conducted the project “Evaluation of clinical impact of drug-drug interactions in metastatic colorectal cancer patients during 5FU-based chemotherapy using Drug-PIN software: A pooled post-hoc analysis of TRIBE and TRIBE2, MOMA, Macbeth, TRIPLETE and Atezo-TRIBE trials” and participated in additional data‑analysis activities on colorectal cancer patients under the supervision of Prof. Chiara Cremolini.

2.    2024/03/15 – 2025/12/31: Authorization for participation in clinical and patient‑care activities for the PhD student within the research project “Evaluation of drug-drug interactions in patients with prostate cancer undergoing therapy with abiraterone, enzalutamide, or apalutamide using the Drug‑PIN software: The ‘DDI‑AID’ study” at the Oncology Unit (UOC) of Policlinico Umberto I.

3.    2025/01/13 – 2025/07/12: Research period at the Department of Bioinformatics, Charité – Universitätsmedizin Berlin. Conducted research projects and data analyses on pharmacological interactions in colorectal and prostate cancer patients under the supervision of Prof. Robert Preissner.

Honours and awards

1.    2015/09/29: 2013–2015 “Percorso di Eccellenza in Translational Medicine”, University of Rome “La Sapienza”. Research project “Personalized Medicine in patients with Multiple Chemical Sensibility”. Tutors: Prof. Guglielmo Bruno and Prof. Maurizio Simmaco.

2.    2023/10/10: Grant – University of Rome “La Sapienza”. Project “Evaluation of clinical impact of drug-drug interactions in metastatic colorectal cancer patients during 5FU-based chemotherapy using Drug‑PIN software: A pooled post-hoc analysis of TRIBE and TRIBE2 studies”, approved by S.A. 263/2023 on 10/10/2023.

3.    Tutor “Percorso Multidisciplinare Diagnostico‑Terapeutico (PDTA) in Oncologia Geriatrica” (Agenas n. 535‑426203, 40 ECM, 31/07/2024–16/12/2024, 2 h/week).

4.    Tutor “Percorso Multidisciplinare Diagnostico‑Terapeutico (PDTA) in Oncologia Geriatrica” (Agenas n. 535‑443655, 50 ECM, 03/03/2025–13/12/2025, 1 h/week).

Certifications
NIDA Clinical Trials Network, 2025/10/23: GOOD CLINICAL PRACTICE certificate. Expiration date 23/10/2028. Mode of learning: Online.

Networks and memberships

1.    2019 – Current: ESMO member.

2.    2020 – Current: AIOM member.

3.    2024 – Current: ASCO member.